

Lecia V Sequist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6685715/publications.pdf>

Version: 2024-02-01

247
papers

50,880
citations

4658

85
h-index

1461

220
g-index

253
all docs

253
docs citations

253
times ranked

37850
citing authors

#	ARTICLE	IF	CITATIONS
1	Anaplastic Lymphoma Kinase Inhibition in Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1693-1703.	27.0	4,141
2	Isolation of rare circulating tumour cells in cancer patients by microchip technology. <i>Nature</i> , 2007, 450, 1235-1239.	27.8	3,272
3	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. <i>Science Translational Medicine</i> , 2011, 3, 75ra26.	12.4	2,938
4	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.	1.6	2,854
5	Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells. <i>New England Journal of Medicine</i> , 2008, 359, 366-377.	27.0	1,602
6	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	7.4	1,386
7	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	10.7	1,369
8	Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. <i>Science Translational Medicine</i> , 2012, 4, 120ra17.	12.4	1,138
9	Overall Survival and Long-Term Safety of Nivolumab (Antiâ€“Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB <i>Clinical Oncology</i> , 2015, 33, 2004-2012.	1.6	1,035
10	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€“Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	7.0	977
11	Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. <i>Cancer Cell</i> , 2010, 17, 77-88.	16.8	956
12	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	9.4	919
13	Inertial Focusing for Tumor Antigenâ€“Dependent and â€“Independent Sorting of Rare Circulating Tumor Cells. <i>Science Translational Medicine</i> , 2013, 5, 179ra47.	12.4	910
14	Lung cancer. <i>Lancet</i> , The, 2021, 398, 535-554.	13.7	896
15	First-Line Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2008, 26, 2442-2449.	1.6	812
16	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology</i> , The, 2015, 16, 830-838.	10.7	786
17	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. <i>Nature Medicine</i> , 2016, 22, 262-269.	30.7	768
18	Acquired resistance to TKIs in solid tumours: learning from lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 473-481.	27.6	740

#	ARTICLE	IF	CITATIONS
19	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. <i>Lancet Oncology</i> , The, 2015, 16, e165-e172.	10.7	685
20	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. <i>Science</i> , 2014, 346, 1480-1486.	12.6	635
21	Rociletinib in <i>EGFR</i> -Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709.	27.0	615
22	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015, 349, 1351-1356.	12.6	614
23	Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 587-595.	1.6	593
24	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1675-1684.	1.6	584
25	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2006, 12, 3908-3914.	7.0	550
26	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520
27	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	1.1	515
28	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015, 6, 6377.	12.8	498
29	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	1.6	470
30	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. <i>Clinical Cancer Research</i> , 2015, 21, 3924-3933.	7.0	459
31	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	12.4	438
32	Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	9.4	429
33	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS</i> , <i>NRAS</i> , or <i>MEK1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2127-33.	7.1	410
34	Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3076-3083.	1.6	402
35	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 539-548.	10.7	390
36	Impact of Epidermal Growth Factor Receptor and <i>KRAS</i> Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. <i>Clinical Cancer Research</i> , 2009, 15, 5267-5273.	7.0	382

#	ARTICLE	IF	CITATIONS
37	Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3307-3315.	1.6	379
38	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	27.8	379
39	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. <i>EMBO Molecular Medicine</i> , 2010, 2, 146-158.	6.9	370
40	Evaluation of BGF398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	1.6	345
41	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined <i>EGFR</i> and <i>RET</i> Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	9.4	342
42	Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4953-4960.	1.6	331
43	Detection of T790M, the Acquired Resistance <i>EGFR</i> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016, 22, 1103-1110.	7.0	326
44	First-Line Afatinib versus Chemotherapy in Patients with Non-“Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 380-390.	1.1	300
45	Osimertinib plus savolitinib in patients with <i>EGFR</i> mutation-positive, <i>MET</i> -amplified, non-small-cell lung cancer after progression on <i>EGFR</i> tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , 2020, 21, 373-386.	10.7	300
46	<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	1.6	286
47	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
48	BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors. <i>Cancer Discovery</i> , 2011, 1, 352-365.	9.4	268
49	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC <i>EGFR</i> Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1690-1700.	1.1	256
50	Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. <i>Nature Communications</i> , 2018, 9, 175.	12.8	248
51	<i>EGFR</i> mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. <i>Neuro-Oncology</i> , 2010, 12, 1193-1199.	1.2	246
52	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2667-2674.	1.6	237
53	A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3068-3077.	7.0	212
54	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. <i>Cancer Discovery</i> , 2014, 4, 1299-1309.	9.4	207

#	ARTICLE	IF	CITATIONS
55	FGFR1 Amplification in Squamous Cell Carcinoma of The Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1775-1780.	1.1	197
56	The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2009, 4, 281-283.	1.1	192
57	RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 541-549.	1.1	189
58	Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 320-326.	2.8	188
59	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 124-129.	1.1	187
60	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016, 22, 2386-2395.	7.0	169
61	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 6399-6413.	5.9	160
62	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	1.6	159
63	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 1372-1387.	9.4	158
64	Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. <i>Cell Reports</i> , 2017, 21, 3298-3309.	6.4	157
65	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	9.4	157
66	Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing. <i>Oncologist</i> , 2007, 12, 90-98.	3.7	156
67	Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. <i>Clinical Cancer Research</i> , 2008, 14, 7060-7067.	7.0	156
68	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	7.0	154
69	EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. <i>Annual Review of Medicine</i> , 2008, 59, 429-442.	12.2	152
70	Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1242-1245.	1.1	140
71	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 499-514.	27.6	140
72	Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. <i>Scientific Reports</i> , 2017, 7, 10936.	3.3	134

#	ARTICLE	IF	CITATIONS
73	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128.	7.1	133
74	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2467-2472.	7.1	131
75	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 391-395.	2.6	128
76	Amplification of <i>CRKL</i> Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-“Small Cell Lung Cancers. Cancer Discovery, 2011, 1, 608-625.	9.4	122
77	Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Oncologist, 2013, 18, 1214-1220.	3.7	119
78	Molecularly Targeted Therapies in Non-“Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	1.1	119
79	Osimertinib in patients with T790M mutation-“positive, advanced non-“small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer, 2019, 125, 892-901.	4.1	117
80	Circulating tumour cells-“monitoring treatment response in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 401-412.	27.6	110
81	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	9.4	107
82	Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. Journal of Clinical Oncology, 2020, 38, 2926-2936.	1.6	107
83	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 2021, 39, 1531-1547.e10.	16.8	106
84	Expression of β -globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications, 2017, 8, 14344.	12.8	96
85	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. Science Translational Medicine, 2017, 9, .	12.4	96
86	Isolation and Molecular Characterization of Circulating Melanoma Cells. Cell Reports, 2014, 7, 645-653.	6.4	91
87	The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers. Annals of Thoracic Surgery, 2013, 96, 962-968.	1.3	90
88	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology, 2021, 16, 162-168.	1.1	90
89	Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 135-140.	1.1	88
90	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	86

#	ARTICLE	IF	CITATIONS
91	Clinical Activity of Alectinib in Advanced RET -Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2027-2032.	1.1	85
92	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 1286-1299.	9.4	85
93	Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1601-1607.	1.1	80
94	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017, 77, 2018-2028.	0.9	80
95	Role of 18 F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2011, 16, 319-326.	3.7	77
96	First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8010-8010.	1.6	77
97	Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2016, 11, e83-e85.	1.1	75
98	<i>AJRCCM</i> : 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1150-1160.	5.6	75
99	Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 4403s-4408s.	7.0	74
100	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. <i>Clinical Cancer Research</i> , 2018, 24, 197-208.	7.0	74
101	Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?. <i>Medicine (United States)</i> 2019;98(10):e16743. doi:10.1093/med/98.10.e16743	1.0	74
102	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.	1.6	74
103	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2022-2026.	1.1	73
104	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 296-302.	1.2	72
105	Update to Rociletinib Data with the RECIST Confirmed Response Rate. <i>New England Journal of Medicine</i> , 2016, 374, 2296-2297.	27.0	72
106	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 1598-1613.	9.4	71
107	Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. <i>Biomaterials</i> , 2015, 65, 93-102.	11.4	70
108	ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9513-9513.	1.6	65

#	ARTICLE	IF	CITATIONS
109	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Nonâ€‘Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	1.1	62
110	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusionâ€‘Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	7.0	62
111	Secondâ€‘Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€‘Small Cell Lung Cancer. <i>Oncologist</i> , 2007, 12, 325-330.	3.7	61
112	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.	1.6	60
113	Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC. <i>Oncologist</i> , 2011, 16, 886-895.	3.7	59
114	Targeting<i>EGFR</i>Exon 20 Insertions in Nonâ€‘Small Cell Lung Cancer: Recent Advances and Clinical Updates. <i>Cancer Discovery</i> , 2021, 11, 2145-2157.	9.4	54
115	Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. <i>Nature Communications</i> , 2017, 8, 1733.	12.8	53
116	A bright future for KRAS inhibitors. <i>Nature Cancer</i> , 2020, 1, 25-27.	13.2	52
117	Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8029-8029.	1.6	52
118	Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Nonâ€‘Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. <i>Clinical Cancer Research</i> , 2008, 14, 6867-6876.	7.0	51
119	Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rocicetinib. <i>JAMA Oncology</i> , 2016, 2, 541.	7.1	49
120	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 6548-6555.	7.0	49
121	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572.	10.7	47
122	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. <i>Oncologist</i> , 2016, 21, 964-973.	3.7	45
123	MET amplification (amp) as a resistance mechanism to osimertinib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9020-9020.	1.6	45
124	Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. <i>Cell Reports</i> , 2019, 27, 3422-3432.e4.	6.4	42
125	Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, S1029-S1039.	1.1	41
126	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	2.8	41

#	ARTICLE	IF	CITATIONS
127	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.. Journal of Clinical Oncology, 2014, 32, 8112-8112.	1.6	41
128	Epidermal Growth Factor Receptorâ€“Mutant Lung Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 371-377.	2.0	40
129	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	1.1	40
130	Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With <i>EGFR</i> Mutations. Journal of Clinical Oncology, 2012, 30, 3330-3336.	1.6	39
131	A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).. Journal of Clinical Oncology, 2013, 31, 8019-8019.	1.6	39
132	Response to Osimertinib inâ€“An EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. Journal of Thoracic Oncology, 2018, 13, e204-e206.	1.1	38
133	Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?. Cancer Imaging, 2019, 19, 36.	2.8	38
134	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1095-1102.	3.7	37
135	Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology, 2010, 5, 1855-1858.	1.1	36
136	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology, 2021, 16, 850-859.	1.1	35
137	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. Journal of Clinical Oncology, 2014, 32, 7514-7514.	1.6	35
138	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 189-194.	1.6	33
139	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic Radiology, 2016, 23, 329-336.	2.5	33
140	Advanced Nonâ€“Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e187-e197.	3.8	33
141	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Research, 2019, 79, 3776-3788.	0.9	32
142	Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8030-8030.	1.6	32
143	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2015, 33, 8001-8001.	1.6	31
144	Treatment of<i>EGFR</i>-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors. JAMA Oncology, 2016, 2, 948.	7.1	30

#	ARTICLE	IF	CITATIONS
145	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7543-7543.	1.6	28
146	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2016, 34, 9044-9044.	1.6	28
147	Epidermal Growth Factor Receptor Mutations in Non-“Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors. Clinical Cancer Research, 2005, 11, 5668-5670.	7.0	27
148	Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist, 2020, 25, 431-437.	3.7	27
149	Targeting <i>FGFR1</i> -amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BCJ398.. Journal of Clinical Oncology, 2014, 32, 8034-8034.	1.6	27
150	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer, 2019, 133, 10-19.	2.0	25
151	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Journal of Thoracic Oncology, 2019, 14, e226-e228.	1.1	24
152	Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2021, 216, 318-329.	2.2	24
153	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer, 2021, 22, 201-209.	2.6	24
154	First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.. Journal of Clinical Oncology, 2013, 31, 2524-2524.	1.6	24
155	Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.. Journal of Clinical Oncology, 2016, 34, 9001-9001.	1.6	23
156	First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation; Positive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2008, 3, S143-S145.	1.1	22
157	Delay of chemotherapy through use of post-progression erlotinib in patients with <i>EGFR</i> -mutant lung cancer.. Journal of Clinical Oncology, 2012, 30, 7547-7547.	1.6	22
158	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. Journal of Clinical Oncology, 2014, 32, 8051-8051.	1.6	22
159	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	1.1	21
160	Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.. Journal of Clinical Oncology, 2015, 33, 8031-8031.	1.6	21
161	Toward Noninvasive Genomic Screening of Lung Cancer Patients. Journal of Clinical Oncology, 2009, 27, 2589-2591.	1.6	20
162	Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. Journal of Thoracic Oncology, 2016, 11, 1522-1528.	1.1	20

#	ARTICLE	IF	CITATIONS
163	Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1360.	3.7	20
164	Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 153-159.e3.	2.6	20
165	Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1389-1396.	1.1	18
166	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8013-8013.	1.6	18
167	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 234-242.	1.9	17
168	Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). <i>Cancer</i> , 2018, 124, 2407-2414.	4.1	17
169	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 792-800.	1.1	17
170	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	17
171	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	17
172	Clinical activity and safety of Anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7509-7509.	1.6	16
173	Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8012-8012.	1.6	16
174	Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review. <i>Journal of Thoracic Oncology</i> , 2016, 11, e135-e139.	1.1	15
175	Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 542-548.	0.6	15
176	Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer. <i>American Journal of Roentgenology</i> , 2020, 214, 766-774.	2.2	15
177	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 44-49.	2.0	14
178	Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. <i>Oncologist</i> , 2019, 24, 1570-1576.	3.7	14
179	Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. <i>Clinical Lung Cancer</i> , 2021, 22, 23-31.	2.6	14
180	High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9586-9586.	1.6	14

#	ARTICLE	IF	CITATIONS
181	A Th1/IFN β Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1725-1735.	7.0	13
182	Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-“Small Cell Lung Cancer. <i>Oncologist</i> , 2011, 16, 1299-1306.	3.7	12
183	Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2280-2282.	1.6	12
184	Unlocking the Mystery of Small-Cell Lung Cancer Transformations in <i>EGFR</i> Mutant Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2987-2988.	1.6	12
185	The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7010-7010.	1.6	12
186	Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9072-9072.	1.6	12
187	A New BATTLE in the Evolving War on Cancer. <i>Cancer Discovery</i> , 2011, 1, 14-16.	9.4	11
188	Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in <i>EGFR</i> -mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7525-7525.	1.6	11
189	Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. <i>Clinical Lung Cancer</i> , 2022, 23, e210-e221.	2.6	11
190	Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR -Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e95-e97.	1.1	10
191	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8015-8015.	1.6	10
192	Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve <i>EGFR</i> -mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9094-9094.	1.6	10
193	Optimal first-line therapy for NSCLC with EGFR mutations. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 71-72.	27.6	9
194	Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7524-7524.	1.6	9
195	LTK fusions: A new target emerges in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 23-25.	16.8	9
196	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-“Transformed <i>EGFR</i> Mutant Non-“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	3.0	8
197	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-“Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	8
198	24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9026-9026.	1.6	8

#	ARTICLE	IF	CITATIONS
199	Treatment of Advanced Non-Small Cell Lung Cancer in the Elderly. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 289-297.	2.1	7
200	Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer. <i>Palliative and Supportive Care</i> , 2013, 11, 223-229.	1.0	7
201	End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. <i>Journal of Palliative Medicine</i> , 2016, 19, 1316-1319.	1.1	7
202	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e655-e665.	2.6	7
203	Modeling Resistance and Recurrence Patterns of Combined Targeted Chemoradiotherapy Predicts Benefit of Shorter Induction Period. <i>Cancer Research</i> , 2020, 80, 5121-5133.	0.9	7
204	Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. <i>Oncologist</i> , 2020, 25, 78-86.	3.7	7
205	Case 31-2011. <i>New England Journal of Medicine</i> , 2011, 365, 1426-1435.	27.0	6
206	Genotyping Lung Cancer Is an Investment in the Future. <i>Journal of Clinical Oncology</i> , 2014, 32, 3576-3577.	1.6	6
207	Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy. <i>Journal of Clinical Oncology</i> , 2014, 32, 8053-8053.	1.6	6
208	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. <i>Oncology and Therapy</i> , 2018, 6, 45-58.	2.6	5
209	Tackling the Next Generation of Resistance in EGFR -Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 419-421.	1.1	4
210	Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib. <i>Journal of Clinical Oncology</i> , 2012, 30, 7556-7556.	1.6	4
211	A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naïve patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2014, 32, 8088-8088.	1.6	4
212	Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2016, 34, 9045-9045.	1.6	4
213	Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. <i>Journal of Clinical Oncology</i> , 2020, 38, 9574-9574.	1.6	4
214	Nazartinib for treatment-naïve EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. <i>European Journal of Cancer</i> , 2022, 172, 276-286.	2.8	4
215	TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study. , 2014, 2, O12.		3
216	Transformation from NSCLC to SCLC: when did it happen? Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e309-e310.	10.7	3

#	ARTICLE	IF	CITATIONS
217	Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology, 2014, 32, 8031-8031.	1.6	3
218	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, TPS9110-TPS9110.	1.6	3
219	Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic. JAMA Network Open, 2022, 5, e224840.	5.9	3
220	Case 23-2008. New England Journal of Medicine, 2008, 359, 405-414.	27.0	2
221	The Role of Liquid Biopsies in Lung Cancer Screening. Seminars in Roentgenology, 2017, 52, 185-187.	0.6	2
222	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.. Journal of Clinical Oncology, 2016, 34, 9000-9000.	1.6	2
223	Abstract 5172: B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma. Cancer Research, 2022, 82, 5172-5172.	0.9	2
224	Brief Report of Biweekly Pemetrexed and Gemcitabine in Elderly Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1170-1173.	1.1	1
225	The Anticipated Next Season of EGFR Inhibitors. Oncologist, 2015, 20, 335-336.	3.7	1
226	Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?. Oncologist, 2015, 20, 1230-1232.	3.7	1
227	Biology of Lung Cancer. , 2016, , 912-926.e6.		1
228	Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib. JACC: CardioOncology, 2019, 1, 179-181.	4.0	1
229	Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde. JTO Clinical and Research Reports, 2021, 2, 100128.	1.1	1
230	A New Era of Protein-Based Assays for Cancer Early Detection. Journal of Thoracic Oncology, 2021, 16, 191-193.	1.1	1
231	Rociletinib-associated cataracts in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2016, 34, 9042-9042.	1.6	1
232	The challenges of repeat biopsies at acquired resistance to EGFR TKIs.. Journal of Clinical Oncology, 2016, 34, e20571-e20571.	1.6	1
233	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8573-8573.	1.6	1
234	Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations.. Journal of Clinical Oncology, 2014, 32, 126-126.	1.6	1

#	ARTICLE	IF	CITATIONS
235	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. <i>Translational Lung Cancer Research</i> , 2013, 2, 411-4.	2.8	1
236	Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9128-9128.	1.6	1
237	Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21154-e21154.	1.6	1
238	Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. , 2019, , 115-131.		0
239	Characteristics of NSCLCs harboring <i>NRAS</i> mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7532-7532.	1.6	0
240	A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apicoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7546-7546.	1.6	0
241	Incidence, characteristics, and survival of patients with <i>EGFR</i> -mutant lung cancers with <i>EGFR T790M</i> at diagnosis identified in the lung cancer mutation consortium (LCMC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8085-8085.	1.6	0
242	Migration to next-generation sequencing and the identification of <i>RET</i> and <i>ROS1</i> rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8094-8094.	1.6	0
243	End of life (EOL) care in patients with metastatic lung cancer harboring <i>EGFR</i> -mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20508-e20508.	1.6	0
244	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	0
245	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21024-e21024.	1.6	0
246	Effect of participation in the <i>EGFR</i> resisters research summit on competence, performance, and professional productivity of young researchers.. <i>Journal of Clinical Oncology</i> , 2022, 40, e23010-e23010.	1.6	0
247	Optimizing supportive care for patients with metastatic lung cancer in the era of precision oncology.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12150-TPS12150.	1.6	0